Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
SCRI Development Innovations, LLC
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University of Wisconsin, Madison
Seoul National University Hospital
Dana-Farber Cancer Institute
Masonic Cancer Center, University of Minnesota
National University Hospital, Singapore
Washington University School of Medicine
Cantonal Hospital of St. Gallen
University of Michigan Rogel Cancer Center
Swedish Medical Center
Third Military Medical University
Taipei Medical University Hospital